Comparison of Nanosized Markers in Lateral Flow Immunoassay of Antibiotic Lincomycin

Olga D Hendrickson,Demid S Popravko,Anatoly V Zherdev,Chuanlai Xu,Kseniya V Serebrennikova,Elena A Zvereva,Boris B Dzantiev

doi:10.3390/iecb2020-07030

Olga D Hendrickson, Demid S Popravko + Show 5 more

Open Access

https://doi.org/10.3390/iecb2020-07030

Copy DOI

Abstract

Improving the sensitivity of the competitive lateral flow immunoassay (LFIA) is important, given the increasing demands for the monitoring of chemical contaminants in food. The choice of nanosized marker is an essential task for improving the LFIA sensitivity. In this study, a CdSe/ZnS quantum dot (QD)-based LFIA combined with a portable reader was developed for rapid and quantitative detection of an antibiotic lincomycin (LIN). The performance of the proposed fluorescence LFIA was compared to the conventional gold nanoparticle (AuNP)-based LFIA realized with the same immunoreagents. The visual cutoff values were 10 ng/mL for AuNP-based LFIA and 20 ng/mL for QD-based LFIA. Furthermore, the instrumental limits of detection have been shown to be comparable for both nanosized markers and amounted to 0.4 ng/mL for AuNPs and 0.2 ng/mL for QDs, respectively. According to the results obtained, both LFIAs may be used for rapid, cost-effective, on-site testing of antibiotics, in particular LIN. However, the QD-based LFIA exhibits lowest limit of detection with the least immunoreagent consumption, which makes it economically beneficial.

Highlights

The lateral flow immunoassay (LFIA) is a common analytical platform for the point-of-care testing of medical diagnostics and environmental monitoring because of its rapidity and simplicity
We developed quantum dot (QD)-based fluorescence LFIA for detection of LIN, followed by a comparison of analytical performance to conventional AuNP-based colorimetric LFIA using the same immunoreagents
The analyses were carried out in the direct competitive format with use of anti-LIN antibodies labeled with AuNPs or QDs

Summary

Introduction

The lateral flow immunoassay (LFIA) is a common analytical platform for the point-of-care testing of medical diagnostics and environmental monitoring because of its rapidity and simplicity. The LFIA provides clear advantages, including the availability of results within a few minutes, the small volume of an analyzed sample, and inexpensive and user-friendly point-of-care testing [1]. The LFIA combines immunochemical reactions with a chromatography principle. It relies on interactions between an analyte and pre-immobilized recognition elements initiated by the addition of a liquid sample. Despite all the advantages mentioned above, the widespread use of LFIAs has been limited by their insufficient sensitivity. Significant effort has been devoted to improving LFIA sensitivity, including the use of alternative labels and detectors, as well as the addition of amplification stages [2,3]

Methods

Results

Conclusion